Radiation Control licenses two key patents from the NIH
Executive Summary
Radiation Control Technologies Inc. (RCT; developing a tumor cell sensitization therapy) has licensed exclusive global rights to two key patents from the National Institutes of Health. The patents cover composition and uses of RCT’s first drug candidate RCT1938 worldwide as a radiosensitizer for cancer, and to treat or prevent radiation exposure.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice